IL-1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation

PURPOSE: Constitutive NF-κB activation is identified in about 70% of pancreatic ductal adenocarcinoma (PDAC) cases and is required for oncogenic KRAS-induced PDAC development in mouse models. We sought to determine whether targeting interleukin-1α (IL-1α) pathway would inhibit NF-κB activity and thu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Zhuang, Zhuonan, Ju, Huaiqiang, Aguilar, Mitzi, Gocho, Takashi, Li, Hao, Iida, Tomonori, Lee, Harold, Fan, Xiaoqiang, Zhou, Haijun, Ling, Jianhua, Li, Zhongkui, Fu, Jie, Wu, Min, Li, Min, Melisi, Davide, Iwakura, Yoichiro, Xu, Kesen, Fleming, Jason B., Chiao, Paul J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6437768/
https://ncbi.nlm.nih.gov/pubmed/26500238
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-3382
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados